FDA issues warning letter to Alkermes, Inc., for misbranding the drug Vivitrol (an extended-release injection formulation of naltrexone) by omitting warnings about the most serious risks associated with the drug from promotional materials
Read more: FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug